- PROCTO3 REPORT AT Gastroenterology, Hepatobiliary, and Biliary Department - FV HOSPITAL (17/01/2024 )
- GLIGCA REPORT AT SPINE DEPARTMENT B – HCMC ORTHOPEDIC TRAUMA HOSPITAL (17/01/2024 )
- REPORT TAMDEFLO, CAPSER, VOCFOR, DEGODAS CAN THO CENTRAL GERD (17/01/2024 )
- REPORT TAMDEFLO ORTHOPEDIC TRAUMA DEPARTMENT (17/01/2024 )
- CAPSER REPORT FOR MUSCULOSCOPIC AND JOINT DEPARTMENT OF CHO RAY HOSPITAL (17/01/2024 )
- TAMDEFLO MINH DUC HOSPITALOn October 21, 2023, Medbolide Joint Stock Company had a report to introduce the product TAMDEFLO (deflazacort 6mg) at the hall of Minh Duc Hospital, Ben Tre. The report took place with the participation of more than 30 Doc (17/01/2024 )
- Report TAMDEFLO Thong Nhat Hospital (17/01/2024 )
- Report TAMDEFLO MEDIC BINH DUONG (17/01/2024 )
- GLIGCA REPORT AT THE PHARMACY DEPARTMENT - FV HOSPITAL (11/01/2024 )
- CAPSER – ENDOCRINE DEPARTMENT, CHO RAY HOSPITAL (16/10/2023 )
VODOCAT REPORT AT HEART DEPARTMENT – PHAP VIET HOSPITAL (FV)
CPDP Medbolide Company organized the seminar "VODOCAT (Torsemide 5 mg) - Breakthrough in diuretics" at the Cardiology Department - French Viet Hospital (FV Hospital) on July 27, 2023. The conference had the participation of MSc. Ho Minh Tuan and doctors specializing in cardiology.
During the conference, the Company presented scientific evidence proving the benefits of Torsemide, which was recognized in the European Journal of Heart Failure and many prestigious specialized journals around the world. VODOCAT (Torsemide 5 mg) offers a new, effective solution to reduce edema in patients with heart failure, kidney failure and cirrhosis.
At the end of the workshop, doctors had the opportunity to discuss and share experiences about using the diuretic drug VODOCAT in heart failure patients. Doctors have expressed satisfaction and trust in VODOCAT (Torsemide 5 mg).
Readers comments